Skip to Content

CombinatoRx Oncology Programs to Be Highlighted at ASH 2009

Preclinical Data on A2A and Beta-2 Adrenergic Receptor Agonist Programs in B-Cell Malignancies To Be Presented

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 24, 2009 - CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that two abstracts highlighting data on its A2A and Beta-2 Adrenergic Receptor Agonist oncology programs have been accepted for presentation at the American Society for Hematology (ASH) 2009 Annual Meeting in New Orleans on December 5-8, 2009.

Poster Presentation:


  • Abstract #3762, Poster Board III-698, Monday, December 7, 2009, 6:00 PM-8:00 PM,

“Adenosine A2A and Beta-2 Adrenergic Receptor Agonist Synergy in B-Cell Malignancies: Selectivity, Breadth of Activity and Effects of Chronic Exposure”, Rickles,, Ernest N. Morial Convention Center, Hall E.


  • Abstract #3831, Poster Board III-767, Monday, December 7, 2009, 6:00 PM-8:00 PM,

“A2A or Beta-2 Adrenergic Receptor Agonist Synergies Induce Distinct Patterns of Gene Expression Relevant to Multiple Myeloma Cell Survival”, Rickles,, Ernest N. Morial Convention Center, Hall E.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action, striking at the biological complexities of human disease. The CombinatoRx proprietary drug discovery technology provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts.

Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx and its B-cell malignancy programs. These forward-looking statements about future expectations, plans and prospects of CombinatoRx, and its B-cell malignancy programs involve significant risks, uncertainties and assumptions, including risks related to CombinatoRx's ability to further develop and obtain regulatory approval for its B-cell malignancy programs and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. These forward looking statements reflect management's current views and CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

Posted: November 2009